|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM150548206 |
| 003 |
DE-627 |
| 005 |
20231223054105.0 |
| 007 |
tu |
| 008 |
231223s2004 xx ||||| 00| ||eng c |
| 028 |
5 |
2 |
|a pubmed24n0502.xml
|
| 035 |
|
|
|a (DE-627)NLM150548206
|
| 035 |
|
|
|a (NLM)15380529
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Wolf, Anna Maria
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Overexpression of indoleamine 2,3-dioxygenase in human inflammatory bowel disease
|
| 264 |
|
1 |
|c 2004
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 26.10.2004
|
| 500 |
|
|
|a Date Revised 19.11.2015
|
| 500 |
|
|
|a published: Print
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a T-cells are causally involved in the pathogenesis of inflammatory bowel disease (IBD). The tryptophan-metabolizing enzyme indoleamine 2,3-dioxygenase (IDO) regulates T-cell proliferation and survival. We show in this report that IDO mRNA is markedly induced in lesional colonic biopsies of IBD patients. IDO is primarily expressed in CD123(+) mononuclear cells infiltrating the submucosal areas of the inflamed lesions. In Crohn's disease (CD), IDO is also strongly expressed in perifollicular regions of lymphoid follicles. Upregulation of IDO is of functional significance, as we detected an increase of kynurenine and of the kynurenine/tryptophan ratio in supernatants from colonic explant cultures (CECs) of CD patients. Immunohistochemistry of colonic biopsies taken from CD patients prior and after treatment with the TNF-blocking antibody Infliximab revealed reduced IDO expression in patients with good clinical response to Infliximab. In summary, high local expression of IDO may represent an anti-inflammatory mechanism tempting to counterbalance the tissue-damaging effects of activated T-cells infiltrating the colonic mucosa in IBD
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
7 |
|a Antibodies, Monoclonal
|2 NLM
|
| 650 |
|
7 |
|a Gastrointestinal Agents
|2 NLM
|
| 650 |
|
7 |
|a Histocompatibility Antigens Class II
|2 NLM
|
| 650 |
|
7 |
|a IL3RA protein, human
|2 NLM
|
| 650 |
|
7 |
|a Indoleamine-Pyrrole 2,3,-Dioxygenase
|2 NLM
|
| 650 |
|
7 |
|a Interleukin-3 Receptor alpha Subunit
|2 NLM
|
| 650 |
|
7 |
|a RNA, Messenger
|2 NLM
|
| 650 |
|
7 |
|a Receptors, Interleukin-3
|2 NLM
|
| 650 |
|
7 |
|a Tumor Necrosis Factor-alpha
|2 NLM
|
| 650 |
|
7 |
|a Infliximab
|2 NLM
|
| 650 |
|
7 |
|a B72HH48FLU
|2 NLM
|
| 650 |
|
7 |
|a Tryptophan Oxygenase
|2 NLM
|
| 650 |
|
7 |
|a EC 1.13.11.11
|2 NLM
|
| 700 |
1 |
|
|a Wolf, Dominik
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Rumpold, Holger
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Moschen, Alexander R
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Kaser, Arthur
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Obrist, Peter
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Fuchs, Dietmar
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Brandacher, Gerald
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Winkler, Christiane
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Geboes, Karel
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Rutgeerts, Paul
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Tilg, Herbert
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 113(2004), 1 vom: 15. Okt., Seite 47-55
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:113
|g year:2004
|g number:1
|g day:15
|g month:10
|g pages:47-55
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 113
|j 2004
|e 1
|b 15
|c 10
|h 47-55
|